Using Mathematical Modeling as a Resource in Clinical Trials
In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of comm...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AIMS Press
2005-07-01
|
| Series: | Mathematical Biosciences and Engineering |
| Subjects: | |
| Online Access: | https://www.aimspress.com/article/doi/10.3934/mbe.2005.2.421 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832590238638145536 |
|---|---|
| author | Evans K. Afenya |
| author_facet | Evans K. Afenya |
| author_sort | Evans K. Afenya |
| collection | DOAJ |
| description | In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of commonality between the model predictions and the clinical findings are investigated as a way of further validating the model predictions and also establishing mathematical foundations for the clinical studies. The model predictions are used to propose additional ways that treatment optimization could enhance the clinical processes. Arising out of these, an expanded model of cancer is proposed and a treatment model is subsequently obtained. These models predict that malignant cells in the marrow and peripheral blood exhibit the tendency to evolve toward population levels that enable them to replace normal cells in these compartments in the untreated case. In the case of dose-dense treatment along with recombinant hematopoietic growth factors, the models predict a situation in which normal and abnormal cells in the marrow and peripheral blood are obliterated by drug action, while the normal cells regain their growth capabilities through growth-factor stimulation. |
| format | Article |
| id | doaj-art-20250d515ddd4e0faa53216de14d8631 |
| institution | Kabale University |
| issn | 1551-0018 |
| language | English |
| publishDate | 2005-07-01 |
| publisher | AIMS Press |
| record_format | Article |
| series | Mathematical Biosciences and Engineering |
| spelling | doaj-art-20250d515ddd4e0faa53216de14d86312025-01-24T01:49:00ZengAIMS PressMathematical Biosciences and Engineering1551-00182005-07-012342143610.3934/mbe.2005.2.421Using Mathematical Modeling as a Resource in Clinical TrialsEvans K. Afenya0Department of Mathematics, Elmhurst College, 190 Prospect Avenue, Elmhurst, IL 60126In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of commonality between the model predictions and the clinical findings are investigated as a way of further validating the model predictions and also establishing mathematical foundations for the clinical studies. The model predictions are used to propose additional ways that treatment optimization could enhance the clinical processes. Arising out of these, an expanded model of cancer is proposed and a treatment model is subsequently obtained. These models predict that malignant cells in the marrow and peripheral blood exhibit the tendency to evolve toward population levels that enable them to replace normal cells in these compartments in the untreated case. In the case of dose-dense treatment along with recombinant hematopoietic growth factors, the models predict a situation in which normal and abnormal cells in the marrow and peripheral blood are obliterated by drug action, while the normal cells regain their growth capabilities through growth-factor stimulation.https://www.aimspress.com/article/doi/10.3934/mbe.2005.2.421clinical trials.leukemiamathematical modelingcancer |
| spellingShingle | Evans K. Afenya Using Mathematical Modeling as a Resource in Clinical Trials Mathematical Biosciences and Engineering clinical trials. leukemia mathematical modeling cancer |
| title | Using Mathematical Modeling as a Resource in Clinical Trials |
| title_full | Using Mathematical Modeling as a Resource in Clinical Trials |
| title_fullStr | Using Mathematical Modeling as a Resource in Clinical Trials |
| title_full_unstemmed | Using Mathematical Modeling as a Resource in Clinical Trials |
| title_short | Using Mathematical Modeling as a Resource in Clinical Trials |
| title_sort | using mathematical modeling as a resource in clinical trials |
| topic | clinical trials. leukemia mathematical modeling cancer |
| url | https://www.aimspress.com/article/doi/10.3934/mbe.2005.2.421 |
| work_keys_str_mv | AT evanskafenya usingmathematicalmodelingasaresourceinclinicaltrials |